Replies to post #99007 on Biotech Values

[DewDiligence]

Currently dominating this market is Lovenox, a low molecular weight heparin, which loses patent protection in a couple of years…

I’m flabbergasted that supposedly reputable publications continue to print this sort of misinformation. As readers of this board presumably know, Sanofi’s US Lovenox patent was invalidated in a final, non-appealable legal judgment in 2008.